Medical Oncology

, Volume 29, Issue 2, pp 1197–1201

Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure

Case Report


We report a case of kappa light chain deposition disease (LCDD) associated with multiple myeloma in a patient presenting with acute renal failure, 2+ proteinuria and hypercalcemia. Serum protein electrophoresis showed an M-spike at 0.1 g/dL. 24-h urine protein electrophoresis showed Bence-Jones proteinuria of 3.8 g. Serum-free light chain assay found excess kappa chains at 3080 mg/L, with normal lambda and an elevated kappa:lambda ratio of 124.7. A kidney biopsy revealed kappa light chain nephropathy with PAS-negative tubular casts in the cortex and outer medulla. Bone marrow biopsy showed 15% kappa-restricted plasma cells. Serum beta-2 microglobulin level was elevated at 7.94 mg/dL. The patient received a 3-day course of plasmapheresis followed by eight cycles of bortezomib (Velcade®), liposomal doxorubicin, and dexamethasone (VDD) and did not require hemodialysis. As partial response was not achieved, treatment was continued with three cycles of bortezomib, cyclophosphamide, dexamethasone, and thalidomide, followed by thalidomide maintenance at 100 mg daily. Thirty-two months after the diagnosis, the patient’s renal function was improved and he achieved a partial response. This case underlines the feasibility and effectiveness of bortezomib-based chemotherapy in the treatment of LCDD with severe renal dysfunction.


Light chain deposition disease Kappa Lambda Renal failure Bortezomib 


  1. 1.
    Randall RE, Williamson WC Jr, Mullinax F, Tung MY, Still WJ. Manifestations of systemic light chain deposition. Am J Med. 1976;69:703–10.Google Scholar
  2. 2.
    Seymour AE, Thompson AJ, Smith PS, Woodroffe AJ, Clarkson AR. Kappa light chain glomerulosclerosis in multiple myeloma. Am J Pathol. 1980;101:557–80.PubMedGoogle Scholar
  3. 3.
    Pozzi C, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42:1154–63.PubMedCrossRefGoogle Scholar
  4. 4.
    Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol. 2001;12:1558–65.PubMedGoogle Scholar
  5. 5.
    Gokden N, Barlogie B, Liapis H. Morphologic heterogeneity of renal light-chain deposition disease. Ultrastruct Pathol. 2008;32(1):17–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Solomon A. Bence-Jones proteins and light chains of immunoglobulins. N Engl J Med. 1976;294:91–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Strober W, Waldmann TA. The role of the kidney in the metabolism of plasma proteins. Nephron. 1974;13:35–66.PubMedCrossRefGoogle Scholar
  8. 8.
    Melmed GM, Fenves AZ, Stone MJ. Urinary findings in renal light chain-derived amyloidosis and light chain deposition disease. Clin Lymphoma Myeloma. 2009;9(3):234–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Ronco P, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006;1:1342–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhu L, Herrera GA, Murphy-Ullrich JE, Huang ZQ, Sanders PW. Pathogenesis of glomerulosclerosis in light chain deposition disease. role for transforming growth factor-beta. Am J Pathol. 1995;147:375–85.PubMedGoogle Scholar
  11. 11.
    Hootkins R, Fenvez AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. Clin Nephrol. 1989;32:75–8.PubMedGoogle Scholar
  12. 12.
    Stratta P, Lazzarich E, Canavese C, Bozzolo C, Monga G. Ciprofloxacin crystal nephropathy. Am J Kidney Dis. 2007;50:330–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis. 1992;20:34–41.PubMedGoogle Scholar
  14. 14.
    Royer B. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int. 2004;65:642–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Lorenz EC. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant. 2008;23:2052–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109:2604–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Hideshima T. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639–47.PubMedCrossRefGoogle Scholar
  18. 18.
    Gilmore TD. Multiple myeloma: lusting for NF-kappaB. Cancer Cell. 2007;12:95–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Johns Hopkins University/Sinai Hospital Program of Internal MedicineBaltimoreUSA
  2. 2.Alvin and Lois Lapidus Cancer Institute, Sinai HospitalBaltimoreUSA

Personalised recommendations